Combination therapy of two Vertex Pharmaceuticals drugs hit a big mark in the treatment of cystic fibrosis.
The volatile biotech sector is experiencing extreme selling on Friday, pushing the NASDAQ down over 2%. The selling has gained in volume and speed as no one wants to be the last trader standing.
Its been a busy summer for biotech, but the coming weeks will heat up with trials from Biodel, Achillon and Coronado, says Adam Feuerstein, Sr. Columnist at TheStreet.
It's time to review the mid-cap biotech stocks reporting second quarter results next week, says Adam Feuerstein, Sr. Columnist at TheStreet.
The only part of Perrigo actually moving to Ireland post the Elan deal is its bank account, says Adam Feuerstein, Sr. Columnist at TheStreet.
Alnylam Pharmaceuticals upcoming meeting is the next big thing in biotech, says TheStreet Sr. columnist Adam Feuerstein.
Biogen Idec's earnings will be the next big thing in biotech says TheStreet Sr. Columnist Adam Feuerstein.
TheStreet senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.
TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.
TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.